On the fly News and insights, exclusive to thefly.com


Crispr Therapeutics

$68.10 /

+9.58 (+16.37%)


William Blair upgrades Crispr Therapeutics to Outperform after 'impressive' data

William Blair analyst Raju Prasad upgraded Crispr Therapeutics to Outperform from Market Perform after the company presented initial results from the ongoing Phase I/II trials of CTX001 for the treatment of beta thalassemia and sickle cell disease. The stock in afternoon trading is up 18%, or $10.29, to $68.82. The analyst says today's data cut was "impressive" as it exceeds the 30% fetal hemoglobin threshold that he viewed as critical. To date, Crispr has shown initial proof-of-concept in beta thalassemia and sickle cell that exceeded expectations and de-risks its wholly owned immuno-oncology platform, Prasad tells investors in a research note. Further, given the "optionality" of the CRISPR-Cas9 platform and potential cost-effectiveness when compared with lentiviral-based therapies, Crispr could be a potential takeout candidate, adds the analyst.

  • 19


  • 07


CRSP Crispr Therapeutics
$68.10 /

+9.58 (+16.37%)

11/19/19 William Blair
Crispr Therapeutics upgraded to Outperform from Market Perform at William Blair
11/19/19 Goldman Sachs
Crispr Therapeutics price target raised to $75 from $52 at Goldman Sachs
11/19/19 Roth Capital
Crispr Therapeutics price target raised to $100 from $65 at Roth Capital
11/19/19 Cantor Fitzgerald
Cantor boosts Vertex target to $229 after 'highly encouraging' data

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.